ATM and ependymoma: PARP1 Inhibition has also been shown to be selectively toxic to ATM-defective tumor cell lines in vitro and to increase radiosensitivity of other ATM-proficient cell lines, including nonsmall-cell lung cancer, medulloblastoma, ependymoma, and high-grade gliomas [33–35].